16.34
+0.275(+1.71%)
Currency In USD
Address
124 Dvora Hanevi'a Street
Tel Aviv, 6944020
Israel
Phone
972 3 914 8213
Website
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
37000
First IPO Date
February 16, 1982
| Name | Title | Pay | Year Born |
| Mr. Richard D. Francis | President, Chief Executive Officer & Director | 6.52M | 1968 |
| Ms. Christine Fox | Executive Vice President of U.S. Commercial Business | 1.92M | 1969 |
| Dr. Eric A. Hughes M.D., Ph.D. | Executive Vice President of Global R&D and Chief Medical Officer | 2M | 1970 |
| Mr. Richard Gordon Daniell | Executive Vice President of European Commercial | 2.13M | 1967 |
| Mr. Eliyahu Sharon Kalif | Executive Vice President & Chief Financial Officer | 2.43M | 1974 |
| Mr. Matthew Shields | Executive Vice President of Global Operations | 0 | 1975 |
| Mr. Christopher J. Stevo CFA | Senior Vice President of Investor Relations & Competitive Intelligence | 0 | N/A |
| Mr. David R. Mcavoy J.D. | Executive Vice President & Chief Legal Officer | 0 | 1963 |
| Mr. Amir Weiss | Senior Vice President & Chief Accounting Officer | 0 | 1977 |
| Kathleen Veit | Senior Vice President, Global Compliance & Ethics Officer | 0 | N/A |
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.